CEL-SCI CORPORATION (CVM) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$5.56M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$5.33M; Depreciation and amortization (m).
- 2025-12-31: Basis Reported; EBITDA (m); Operating income -$5.37M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$5.49M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$5.56M | (m) | (m) | (m) | $0.00* | -$4.03M* | (m) | $3.65M | (m) | (m) |
| 2026-03-31 | Reported | (m) | -$5.33M | (m) | (m) | (m) | $0.00* | -$4.02M* | (m) | $3.77M | (m) | (m) |
| 2025-12-31 | Reported | (m) | -$5.37M | (m) | (m) | (m) | $0.00 | -$4.02M | (m) | $3.68M | (m) | (m) |
| 2025-06-30 | Reported | (m) | -$5.49M | (m) | (m) | (m) | $0.00* | -$3.94M* | (m) | $3.74M | (m) | (m) |
| 2025-03-31 | Reported | (m) | -$6.39M | (m) | (m) | (m) | $0.00* | -$4.37M* | (m) | $4.01M | (m) | (m) |
| 2024-12-31 | Reported | (m) | -$6.89M | (m) | (m) | (m) | $32.95K | -$4.14M | (m) | $4.43M | (m) | (m) |
| 2024-06-30 | Reported | (m) | -$6.67M | (m) | (m) | (m) | $23.47K* | -$4.58M* | (m) | $4.70M | (m) | (m) |
| 2024-03-31 | Reported | (m) | -$7.08M | (m) | (m) | (m) | $0.00* | -$4.53M* | (m) | $4.63M | (m) | (m) |
| 2023-12-31 | Reported | (m) | -$6.49M | (m) | (m) | (m) | $51.65K | -$4.89M | (m) | $4.35M | (m) | (m) |
| 2023-06-30 | Reported | (m) | -$8.18M | (m) | (m) | (m) | $196.86K* | -$5.67M* | (m) | $5.73M | (m) | (m) |
| 2023-03-31 | Reported | (m) | -$8.18M | (m) | (m) | (m) | $111.45K* | -$7.47M* | (m) | $6.08M | (m) | (m) |
| 2022-12-31 | Reported | (m) | -$7.65M | (m) | (m) | (m) | $53.58K | -$4.67M | (m) | $5.39M | (m) | (m) |
| 2022-06-30 | Reported | (m) | -$8.72M | (m) | (m) | (m) | $70.97K* | -$5.79M* | (m) | $6.29M | (m) | (m) |
| 2022-03-31 | Reported | (m) | -$9.55M | (m) | (m) | (m) | $533.83K* | -$2.73M* | (m) | $6.52M | (m) | (m) |
| 2021-12-31 | Reported | (m) | -$8.84M | (m) | (m) | (m) | $17.04K | -$4.81M | (m) | $6.08M | (m) | (m) |
| 2021-06-30 | Reported | (m) | -$10.46M | (m) | (m) | (m) | $2.00M* | -$5.20M* | (m) | $7.18M | (m) | (m) |
| 2021-03-31 | Reported | (m) | -$8.53M | (m) | (m) | (m) | $3.48M* | -$4.96M* | (m) | $5.22M | (m) | (m) |
| 2020-12-31 | Reported | (m) | -$8.73M | (m) | (m) | (m) | $3.15M | -$3.83M | (m) | $5.41M | (m) | (m) |
| 2020-06-30 | Reported | (m) | -$6.97M | (m) | (m) | (m) | $777.53K* | -$3.70M* | (m) | $3.97M | (m) | (m) |
| 2020-03-31 | Reported | (m) | -$6.72M | (m) | (m) | (m) | $650.98K* | -$3.89M* | (m) | $4.46M | (m) | (m) |
| 2019-12-31 | Reported | (m) | -$6.86M | (m) | (m) | (m) | $101.82K | -$4.10M | (m) | $4.25M | (m) | (m) |
| 2019-06-30 | Reported | (m) | -$5.21M | (m) | (m) | (m) | -$332.24K* | -$4.64M* | (m) | $2.97M | (m) | (m) |
| 2019-03-31 | Reported | (m) | -$4.31M | (m) | (m) | (m) | $154.79K* | -$3.63M* | (m) | $2.83M | (m) | (m) |
| 2018-12-31 | Reported | (m) | -$5.03M | (m) | (m) | (m) | $6.13K | -$4.16M | (m) | $3.47M | (m) | (m) |
| 2018-06-30 | Reported | (m) | -$4.09M | (m) | (m) | (m) | $1.01K* | -$2.78M* | (m) | $2.43M | (m) | (m) |
| 2018-03-31 | Reported | (m) | -$4.22M | (m) | (m) | (m) | $0.00* | -$3.75M* | (m) | $2.96M | (m) | (m) |
| 2017-12-31 | Reported | (m) | -$4.93M | (m) | (m) | (m) | $0.00 | -$2.61M | (m) | $2.33M | (m) | (m) |
| 2017-06-30 | Reported | (m) | -$4.76M | (m) | (m) | (m) | $0.00* | -$3.13M* | (m) | $3.18M | (m) | (m) |
| 2017-03-31 | Reported | (m) | -$7.91M | (m) | (m) | (m) | $10.53K* | -$2.99M* | (m) | $6.58M | (m) | (m) |
| 2016-12-31 | Reported | (m) | -$4.94M | (m) | (m) | (m) | $0.00 | -$4.24M | (m) | $3.55M | (m) | (m) |
| 2016-06-30 | Reported | (m) | -$5.91M | (m) | (m) | (m) | $9.76K* | -$5.42M* | (m) | $4.36M | (m) | (m) |
| 2016-03-31 | Reported | (m) | -$5.80M | (m) | (m) | (m) | $6.81K* | -$4.96M* | (m) | $4.15M | (m) | (m) |
| 2015-12-31 | Reported | (m) | -$5.31M | (m) | (m) | (m) | $14.83K | -$5.84M | (m) | $4.69M | (m) | (m) |
| 2015-06-30 | Reported | (m) | -$8.20M | (m) | (m) | (m) | $0.00* | -$6.25M* | (m) | $5.73M | (m) | (m) |
| 2015-03-31 | Reported | (m) | -$7.76M | (m) | (m) | (m) | $39.52K* | -$6.80M* | (m) | $5.08M | (m) | (m) |
| 2014-12-31 | Reported | (m) | -$10.00M | (m) | (m) | (m) | $17.10K | -$5.44M | (m) | $4.85M | (m) | (m) |
| 2014-06-30 | Reported | (m) | -$6.90M | (m) | (m) | (m) | $39.49K* | -$6.02M* | (m) | $4.45M | (m) | (m) |
| 2014-03-31 | Reported | (m) | -$6.23M | (m) | (m) | (m) | $18.83K* | -$5.26M* | (m) | $4.15M | (m) | (m) |
| 2013-12-31 | Reported | (m) | -$5.93M | (m) | (m) | (m) | $8.59K | -$5.92M | (m) | $4.02M | (m) | (m) |
| 2013-06-30 | Reported | (m) | -$5.51M | (m) | (m) | (m) | $16.58K* | -$3.47M* | (m) | $3.77M | (m) | (m) |
| 2013-03-31 | Reported | (m) | -$4.24M | (m) | (m) | (m) | $60.74K* | -$3.68M* | (m) | $2.52M | (m) | (m) |
| 2012-12-31 | Reported | (m) | -$5.04M | (m) | (m) | (m) | $16.09K | -$2.99M | (m) | $2.92M | (m) | (m) |
| 2012-06-30 | Reported | -$4.10M* | -$4.21M | $112.17K | (m) | (m) | $12.41K* | -$3.13M* | (m) | $2.47M | (m) | (m) |
| 2012-03-31 | Reported | (m) | -$4.26M | (m) | (m) | (m) | $14.34K* | -$3.18M* | (m) | $2.59M | (m) | (m) |
| 2011-12-31 | Reported | (m) | -$4.44M | (m) | (m) | (m) | $16.47K | -$2.61M | (m) | $2.46M | (m) | (m) |
| 2011-06-30 | Reported | (m) | (m) | (m) | (m) | -6097.06% | $78.41K* | -$7.18M* | (m) | $2.92M | (m) | $0.00 |
| 2011-03-31 | Reported | (m) | -$5.10M | (m) | (m) | (m) | $68.86K* | -$4.11M* | (m) | $3.04M | (m) | (m) |
| 2010-12-31 | Reported | (m) | -$4.32M | (m) | (m) | (m) | $27.73K | -$6.43M | (m) | $3.26M | (m) | (m) |
| 2010-06-30 | Reported | (m) | -$3.39M | (m) | (m) | (m) | (m) | (m) | (m) | $1.59M | (m) | $0.00 |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | Reported | -$22.75M* | -$24.81M | $2.06M | (m) | (m) | $38.11K | -$17.12M | (m) | $15.89M | (m) | (m) |
| 2024-09-30 | Reported | -$24.22M* | -$26.35M | $2.13M | (m) | (m) | $94.88K | -$18.81M | (m) | $18.16M | (m) | (m) |
| 2023-09-30 | Reported | -$29.36M* | -$31.48M | $2.11M | (m) | (m) | $361.89K | -$22.85M | (m) | $22.47M | (m) | (m) |
| 2022-09-30 | Reported | -$34.09M* | -$36.06M | $1.98M | (m) | (m) | $637.89K | -$18.24M | (m) | $25.36M | (m) | (m) |
| 2021-09-30 | Reported | -$35.75M* | -$36.19M | $447.00K | (m) | (m) | $9.02M | -$18.79M | (m) | $23.11M | (m) | (m) |
| 2020-09-30 | Reported | -$28.60M* | -$28.99M | $389.00K | (m) | (m) | $2.65M | -$15.28M | (m) | $17.84M | (m) | (m) |
| 2019-09-30 | Reported | -$19.61M* | -$20.20M | $588.00K | (m) | (m) | -$177.78K | -$16.32M | (m) | $12.66M | (m) | (m) |
| 2018-09-30 | Reported | -$16.20M* | -$16.77M | $575.00K | (m) | (m) | $1.01K | -$13.39M | (m) | $10.91M | (m) | (m) |
| 2017-09-30 | Reported | -$20.81M* | -$21.41M | $593.00K | (m) | (m) | $10.53K | -$13.79M | (m) | $15.61M | (m) | (m) |
| 2016-09-30 | Reported | -$23.02M* | -$23.65M | $626.00K | (m) | (m) | $31.41K | -$23.08M | (m) | $17.45M | (m) | (m) |
| 2015-09-30 | Reported | -$31.71M* | -$32.39M | $680.00K | (m) | (m) | $73.40K | -$23.83M | (m) | $19.19M | (m) | (m) |
| 2014-09-30 | Reported | (m) | (m) | (m) | (m) | -10371.86% | $103.98K | -$22.93M | (m) | $15.27M | (m) | (m) |
| 2013-09-30 | Reported | (m) | (m) | (m) | (m) | -12277.22% | $102.03K | -$13.55M | (m) | $12.68M | (m) | (m) |
| 2012-09-30 | Reported | (m) | (m) | (m) | (m) | -6596.63% | $54.64K | -$12.19M | (m) | $10.37M | (m) | (m) |
| 2011-09-30 | Reported | (m) | -$17.99M | (m) | (m) | (m) | $216.76K | -$22.56M | (m) | $11.75M | (m) | (m) |
| 2010-09-30 | Reported | (m) | -$18.56M | (m) | (m) | (m) | $493.74K | -$12.80M | (m) | $11.91M | (m) | (m) |
| 2009-09-30 | Reported | (m) | -$12.02M | (m) | (m) | (m) | -$191.87K | -$6.51M | (m) | $6.01M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |